Synergistic Provoking of Pyroptosis and STING Pathway by Multifunctional Manganese-Polydopamine Nano-Immunomodulator for Enhanced Renal Cell Carcinoma Immunotherapy
- PMID: 40394938
- DOI: 10.1002/adhm.202500141
Synergistic Provoking of Pyroptosis and STING Pathway by Multifunctional Manganese-Polydopamine Nano-Immunomodulator for Enhanced Renal Cell Carcinoma Immunotherapy
Abstract
Manganese ions are known to enhance anti-tumor immunity by activating the cGAS-STING signaling pathway. However, precise modulation of the tumor microenvironment using manganese ions remains a challenge. Dopamine, with its controlled release properties within the tumor microenvironment, offers significant potential for precision drug delivery systems. Metastatic renal cell carcinoma (RCC), being refractory to conventional treatments, necessitates innovative therapeutic approaches. In this study, a multifunctional manganese-polydopamine nano-immunomodulator coated with hyaluronic acid (PDA-Mn-HA NPs) is developed. These nanoparticles selectively bind to CD44 molecules, which are highly expressed in tumor-associated macrophages and RCC cells, and release manganese ions in a tumor microenvironment-responsive manner. Treatment with PDA-Mn-HA NPs effectively induces macrophage M1 polarization, triggers the production of pro-inflammatory cytokines and chemokines. Transcriptomic analysis reveals that PDA-Mn-HA NPs polarize and activate macrophages through the reactive oxygen species(ROS)-STING-p38/MAPK signaling pathway. Additionally, PDA-Mn-HA NPs induce ROS-caspase-3/GSDME-dependent pyroptosis in RCC cells via a Fenton-like reaction. In RCC mouse models, PDA-Mn-HA NPs remodel the macrophage-mediated immune microenvironment, enhance immune cell infiltration, and significantly suppress tumor growth. In conclusion, multifunctional PDA-Mn-HA NPs demonstrate translational potential by addressing the limitations of precision manganese delivery and achieving synergistic targeting of macrophages and tumor cells, offering a promising therapeutic strategy for RCC.
Keywords: cGAS‐STING; manganese; nano‐immunomodulator; pyroptosis; renal cell carcinoma.
© 2025 Wiley‐VCH GmbH.
Similar articles
-
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment.Mol Cancer. 2025 Jun 18;24(1):181. doi: 10.1186/s12943-025-02382-y. Mol Cancer. 2025. PMID: 40533745 Free PMC article.
-
Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma.Oncogene. 2024 May;43(20):1534-1548. doi: 10.1038/s41388-024-03013-4. Epub 2024 Mar 28. Oncogene. 2024. Retraction in: Oncogene. 2025 Aug 8. doi: 10.1038/s41388-025-03526-6. PMID: 38548966 Retracted.
-
Multifunctional nanoagent for enhanced cancer radioimmunotherapy via pyroptosis and cGAS-STING activation.J Nanobiotechnology. 2025 Jul 21;23(1):527. doi: 10.1186/s12951-025-03608-3. J Nanobiotechnology. 2025. PMID: 40685365 Free PMC article.
-
Nanocarrier-mediated modulation of cGAS-STING signaling pathway to disrupt tumor microenvironment.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul;398(7):7667-7695. doi: 10.1007/s00210-025-03835-3. Epub 2025 Feb 5. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39907784 Review.
-
Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC).Int J Mol Sci. 2025 Jun 11;26(12):5577. doi: 10.3390/ijms26125577. Int J Mol Sci. 2025. PMID: 40565041 Free PMC article. Review.
References
-
- a) H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Ca‐Cancer J. Clin. 2021, 71, 209;
-
- b) L. Bukavina, K. Bensalah, F. Bray, M. Carlo, B. Challacombe, J. A. Karam, W. Kassouf, T. Mitchell, R. Montironi, T. O'Brien, V. Panebianco, G. Scelo, B. Shuch, H. van Poppel, C. D. Blosser, S. P. Psutka, European Urology 2022, 82, 529.
-
- a) D. A. Braun, Z. Bakouny, L. Hirsch, R. Flippot, E. M. Van Allen, C. J. Wu, T. K. Choueiri, Nat. Rev. Clin. Oncol. 2021, 18, 199;
-
- b) A. Deleuze, J. Saout, F. Dugay, B. Peyronnet, R. Mathieu, G. Verhoest, K. Bensalah, L. Crouzet, B. Laguerre, M.‐A. Belaud‐Rotureau, N. Rioux‐Leclercq, S.‐F. Kammerer‐Jacquet, Int. J. Mol. Sci. 2020, 21, 2532.
-
- a) B. I. Rini, E. R. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulières, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S. J. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R. S. McDermott, J. Bedke, S. Tartas, Y.‐H. Chang, S. Tamada, Q. Shou, R. F. Perini, M. Chen, M. B. Atkins, T. Powles, N. Engl. J. Med. 2019, 380, 1116;
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous